This announcement is a separate document:
康方生物：自願公告 - 卡度尼利聯合化療一線治療胃或胃食管結合部腺癌的III期臨床試驗(AK104 -302)的期中分析達到總生存期(OS)主要終點
AKESO: VOLUNTARY ANNOUNCEMENT - AK104-302, A PHASE III TRIAL OF CADONILIMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST LINE TREATMENT FOR GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GC/GEJC) REACHED PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS) AT INT
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.